Wak­sal's gene ther­a­py spin­off MeiraGTx says it’s time to fly with an $86M IPO

Three years af­ter Sam Wak­sal’s Kad­mon spun out its gene ther­a­py tech in­to a start­up called MeiraGTx, the New York-based biotech says it’s ready to come out to play on Nas­daq.

Wak­sal, an ex-con once sen­tenced to prison for his in­sid­er trad­ing con­vic­tion in­volv­ing Martha Stew­art, had to leave Kad­mon be­fore the com­pa­ny was able to com­plete its own IPO. And now his brain­child — un­der the di­rec­tion of for­mer Kad­mon com­mer­cial chief Alexan­dria Forbes — has pen­ciled in an $86 mil­lion raise in its own S-1.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.